SCHEMBL201033

SCHEMBL201033

O=C(O)c1ccccc1C(=O)N[C@H](Cc1c[nH]cn1)C(=O)NO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
ITGB2 P05107 2/20 0.39
ICAM1 P05362 2/20 0.39
ITGAL P20701 2/20 0.39
ANPEP P15144 1/20 0.38
HDAC7 Q8WUI4 1/20 0.37
PADI1 Q9ULC6 1/20 0.36
PADI3 Q9ULW8 1/20 0.36
PADI4 Q9UM07 1/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
APEX1 P27695 1/20 0.35
FCER2 P06734 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201034 1.00 HDAC3 (0.39) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL3864877 0.89 ITGB2 (0.45) ITGB2ICAM1ITGALPADI1PADI3
SCHEMBL2751866 0.85 CAPN1 (0.37) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL11622266 0.79 ANPEP (0.59) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL254686 0.76 MMP2 (0.39) HDAC3HDAC4HDAC1HDAC2HDAC8
SCHEMBL31310188 0.75 GPR139 (0.39)
SCHEMBL1310656 0.75 ACE (0.48) ITGB2ICAM1ITGALKMT2A
SCHEMBL1310658 0.75 ACE (0.48) ITGB2ICAM1ITGALKMT2A
SCHEMBL9828293 0.75 BACE1 (0.49)
SCHEMBL9828282 0.75 BACE1 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4099010-A PHTHALOYL AMINO ACID HYDROXAMIC ACIDS MORTON-NORWICH PRODUCTS, INC. (US) 1978-07-04 US claimed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
US-4099010-A PHTHALOYL AMINO ACID HYDROXAMIC ACIDS MORTON-NORWICH PRODUCTS, INC. (US) 1978-07-04 US disclosed
US-4077998-A Phthaloyl amino acid hydroxamic acids MORTON-NORWICH PRODUCTS, INC. (US) 1978-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 HDAC3 1037/4885HDAC4 533/4885HDAC1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.